New Biomarkers of Chronic Hepatitis B

키워드

참고문헌 (48)

1. Yuen MF, "Hepatitis B virus infection", Nat Rev Dis Primers, 4, pp.18035~ (2018)
2. Lai CL, "The natural history and treatment of chronic hepatitis B : a critical evaluation of standard treatment criteria and end points", Ann Intern Med, 147, pp.58~61 (2007)
3. European Association for the Study of the Liver, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
4. Zoulim F, "New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA", J Hepatol, 42, pp.302~308 (2005)
5. Mason AL, "Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen", Hepatology, 27, pp.1736~1742 (1998)
6. Yuen MF, "HBsAg seroclearance in chronic hepatitis B in Asian patients : replicative level and risk of hepatocellular carcinoma", Gastroenterology, 135, pp.1192~1199 (2008)
7. Fung J, "Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance", Hepatology, 68, pp.462~472 (2018)
8. Kim GA, "HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B : clinical outcomes and durability", Gut, 63, pp.1325~1332 (2014)
9. Liu J, "Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance : a community-based follow-up study", Gastroenterology, 139, pp.474~482 (2010)
10. Durantel D, "New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus", J Hepatol, 64, pp.S117~S131 (2016)
11. Kimura T, "Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain", J Biol Chem, 280, pp.21713~21719 (2005)
12. Kimura T, "Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load", J Clin Microbiol, 40, pp.439~445 (2002)
13. Maasoumy B, "Hepatitis B core-related antigen(HBcrAg)levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D", Clin Microbiol Infect, 21, pp.606~ (2015)
14. Seto WK, "Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B", Clin Microbiol Infect, 20, pp.1173~1180 (2014)
15. Seto WK, "Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay", Hepatol Int, 7, pp.98~105 (2012)
16. Rokuhara A, "Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection", J Gastroenterol Hepatol, 20, pp.1726~1730 (2005)
17. Rokuhara A, "Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment", J Viral Hepat, 10, pp.324~330 (2003)
18. Wong DK, "Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection", J Clin Microbiol, 45, pp.3942~3947 (2007)
19. Wong DK, "Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA", Liver Int, 37, pp.995~1001 (2017)
20. Lam YF, "Seven-year treatment outcome of entecavir in a real-world cohort : effects on clinical parameters, HBsAg and HBcrAg levels", Clin Transl Gastroenterol, 8, pp.e125~ (2017)
21. Suzuki F, "Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients", J Med Virol, 81, pp.27~33 (2009)
22. Lai CL, "Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B", J Hepatol, 66, pp.275~281 (2017)
23. Ma H, "HBcrAg identifies patients failing to achieve HBeAg seroconversion treated with pegylated interferon Alfa-2b", Chin Med J(Engl), 129, pp.2212~2219 (2016)
24. Yuen MF, "Differential reductions in viral antigens expressed from CCCDNAVS integrated DNA in treatment naïve HBEAG positive and negative patients with chronic HBV after RNA interference therapy with ARC-520", J Hepatol, 64, pp.S390~S391 (2016)
25. Tada T, "HBcrAg predicts hepatocellular carcinoma development : an analysis using time-dependent receiver operating characteristics", J Hepatol, 65, pp.48~56 (2016)
26. Cheung KS, "Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy", J Viral Hepat, 24, pp.654~661 (2017)
27. Seto WK, "Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy", Am J Gastroenterol, 111, pp.1788~1795 (2016)
28. 이한아, "Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B", Clinical and Molecular Hepatology, 22(3), pp.382~389 (2016), 대한간학회
29. Jung KS, "Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients", J Gastroenterol, 51, pp.830~839 (2016)
30. Mak LY, "Review article : hepatitis B core-related antigen(HBcrAg) : an emerging marker for chronic hepatitis B virus infection", Aliment Pharmacol Ther, 47, pp.43~54 (2018)
31. Gerelsaikhan T, "Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis", J Virol, 70, pp.4269~4274 (1996)
32. Perlman D, "Duck hepatitis B virus virion secretion requires a double-stranded DNA genome", J Virol, 77, pp.2287~2294 (2003)
33. Wang J, "Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound", J Hepatol, 65, pp.700~710 (2016)
34. Rokuhara A, "Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy", J Gastroenterol, 41, pp.785~790 (2006)
35. Jansen L, "Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues", J Infect Dis, 213, pp.224~232 (2016)
36. Hatakeyama T, "Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine", Hepatology, 45, pp.1179~1186 (2007)
37. Kurosaki M, "Serum HBV RNA as a possible marker of HBV replication in the liver during nucleot(s)ide analogue therapy", J Gastroenterol, 48, pp.777~778 (2013)
38. Su Q, "Circulating hepatitis B virus nucleic acids in chronic infection : representation of differently polyadenylated viral transcripts during progression to nonreplicative stages", Clin Cancer Res, 7, pp.2005~2015 (2001)
39. van Bömmel F, "Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors", Hepatology, 61, pp.66~76 (2015)
40. Huang YW, "On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy", Antivir Ther, 20, pp.369~375 (2015)
41. Tsuge M, "Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients", J Gastroenterol, 48, pp.1188~1204 (2013)
42. Butler EK, "HBV serum DNA and RNA levels in nucleos(t)ide analogue-treated or untreated patients during chronic and acute infection", Hepatology, 68, pp.2016~2117 (2018)
43. Wang J, "Natural history of serum HBV-RNA in chronic HBV infection", J Viral Hepat, 25, pp.1038~1047 (2018)
44. Gao Y, "Serum hepatitis B virus DNA, RNA, and HBsAg : which correlated better with intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment", J Clin Microbiol, 55, pp.2972~2982 (2017)
45. Wang J, "Reply to : "Serum HBV pgRNA as a clinical marker for cccDNA activity" : consistent loss of serum HBV RNA might predict the"para-functional cure"of chronic hepatitis B", J Hepatol, 66, pp.462~463 (2017)
46. Yuen MF, "NVR3-778, a first-in-class HBV core inhibitor, alone and in combination with Peg-interferon(PegIFN), in treatment-naive HBeAg-positive patients : early reductions in HBV DNA and HBeAg", J Hepatol, 64, pp.S210~ (2016)[DOI]
47. Yuen MF, "SB 9200 an oral selective immunomodulator is safe and efficacious in treatment-naive, non-cirrhotic HBV patients : results from cohort 1 of the ACHIEVE trial", Hepatology, 66, pp.22~23A (2017)
48. Sato S, "The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus", Immunity, 42, pp.123~132 (2015)

관련 논문AI추천